Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.

Article Details

Citation

Copy to clipboard

Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H

Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.

J Clin Pharmacol. 2005 Mar;45(3):337-45.

PubMed ID

15703368 [ View in PubMed

]

Abstract

Two 14-day, randomized, open-label, parallel-group studies examined the effects of extended-release (ER) oxymorphone on CYP2C9 or CYP3A4 metabolic activities in healthy subjects. On days -1, 7, and 14, subjects received either a CYP2C9 probe (tolbutamide 500 mg) or CYP3A4 probes (midazolam and [14C N-methyl]-erythromycin for the erythromycin breath test). Subjects were randomized to 5 groups: high-dose oxymorphone ER (3 x 20 mg q12h) + naltrexone (50 mg q24h); low-dose oxymorphone ER (10-20 mg q12h); rifampin (2 x 300 mg q24h), an inducer of CYP2C9 and CYP3A4 activities; naltrexone (50 mg q24h); or CYP probes alone (controls). Probe metabolism was significantly altered by rifampin on days 7 and 14 (P < .05), whereas probe metabolism was not significantly affected by low-dose oxymorphone ER or by high-dose oxymorphone ER plus naltrexone. Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Oxymorphone	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate	Details